ALNYLAM PHARMACEUTICALS, INC. Balance Sheet
ALNY / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 15 fiscal years. All figures from audited SEC 10-K filings.
ALNYLAM PHARMACEUTICALS, INC. had $5.0B in total assets and $789M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.37 (distress zone, below 1.8 threshold)
- Negative profit margin: -12.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.7B | $966.4M | $812.7M | $866.4M | $820.0M | $496.6M | $420.1M | $420.1M | $645.4M | $193.6M | $180.9M | $75.2M | $53.2M | $51.4M | $70.2M |
| Accounts Receivable | $777.6M | $405.3M | $327.8M | $238.0M | $198.6M | $102.4M | $43.0M | $18.8M | $34.0M | - | - | - | - | - | - |
| Inventory | $82.7M | $78.5M | $89.1M | $129.0M | $86.4M | $75.2M | $56.3M | $24.1M | - | - | - | - | - | - | - |
| Current Assets | $4.1B | $3.3B | $3.0B | $2.7B | $2.8B | $2.6B | $1.7B | $1.2B | $1.8B | $671.9M | $1.1B | $746.4M | $254.0M | $125.6M | $152.0M |
| PP&E (Net) | $513.1M | $502.8M | $526.1M | $523.5M | $502.0M | $465.0M | $425.2M | $320.7M | $181.9M | $114.6M | $27.8M | $21.7M | $16.4M | $19.8M | $14.6M |
| Total Assets | $5.0B | $4.2B | $3.8B | $3.5B | $3.6B | $3.4B | $2.4B | $1.6B | $2.0B | $1.3B | $1.4B | $1.1B | $420.5M | $287.5M | $281.9M |
| Current Liabilities | $1.5B | $1.2B | $967.8M | $767.9M | $695.7M | $585.3M | $352.6M | $179.5M | $144.3M | $131.7M | $62.1M | $95.3M | $53.9M | $48.3M | $81.0M |
| Shareholders' Equity | $789.2M | $67.1M | -$220.6M | -$158.2M | $588.2M | $1.0B | $1.8B | $1.3B | $1.8B | $920.2M | $1.3B | $936.3M | $270.3M | $134.1M | $118.0M |